- Title: Subtitle
- 288MO Update from the long-term follow-up (LTFU) phase of ReNeu: A pivotal phase IIb trial of mirdametinib in adults and children with neurofibromatosis type 1 (NF1)-associated symptomatic plexiform neurofibroma (PN)
- Creators
- A. Hirbe - Washington University in St. LouisH. Shuhaiber - University of FloridaD. Viskochil - University of UtahA. Sidhu - University of Iowa Health CareJ. Meade - University of PittsburghL. Weintraub - Albany Medical Center HospitalA. Langseth - United Therapeutics (United States)M. Weber - Spring Bank Pharmaceuticals (United States)A. Lokku - Spring Bank Pharmaceuticals (United States)F. Hajjar - AdventHealth for ChildrenR. Antony - University of California, DavisD. Schiff - University of Virginia Medical CenterA. Raslan - Oregon Health & Science UniversityK. Nevel - Indiana University HealthD. Babovic-Vuksanovic - Mayo ClinicT. Gershon - Emory University
- Resource Type
- Abstract
- Publication Details
- ESMO Rare Cancers, Vol.5(Supplement), 100213
- DOI
- 10.1016/j.esmorc.2026.100213
- ISSN
- 3050-4619
- Publisher
- Elsevier Ltd
- Language
- English
- Date published
- 03/2026
- Academic Unit
- Stead Family Department of Pediatrics; Medical Genetics and Genomics
- Record Identifier
- 9985147202602771
Abstract
288MO Update from the long-term follow-up (LTFU) phase of ReNeu: A pivotal phase IIb trial of mirdametinib in adults and children with neurofibromatosis type 1 (NF1)-associated symptomatic plexiform neurofibroma (PN)
ESMO Rare Cancers, Vol.5(Supplement), 100213
03/2026
DOI: 10.1016/j.esmorc.2026.100213
Details
Metrics
1 Record Views